Rapt Therapeutics winds down Phase 2 studies of lead candidate in wake of clinical holds
Rapt Therapeutics said it will close and unblind two mid-stage trials in atopic dermatitis and asthma after they were put on clinical hold earlier this …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
